S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.48 (+1.97%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.48 (+1.97%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.48 (+1.97%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.48 (+1.97%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-4.01%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
LON:SAR

Sareum - SAR Share Forecast, Price & News

GBX 172.50
+4.50 (+2.68%)
(As of 08/12/2022 04:22 PM ET)
Add
Compare
Today's Range
161
175
50-Day Range
160
221.77
52-Week Range
92.50
455
Volume
67,589 shs
Average Volume
150,803 shs
Market Capitalization
£117.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
SAR stock logo

About Sareum (LON:SAR) Stock

Sareum Holdings plc, a specialist drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company's product pipeline includes Checkpoint Kinase 1, Aurora+FLT3 kinase, and TYK2/JAK1 kinase. It has collaborations with Hebei Medical University Biomedical Engineering Center and Sierra Oncology, Inc. The company was founded in 2003 and is based in Cambridge, the United Kingdom.

Sareum Stock Performance

Shares of SAR Stock opened at GBX 163 ($1.97) on Friday. The firm has a market cap of £110.95 million and a P/E ratio of -62.22. The firm's 50 day moving average price is GBX 191.15 and its 200-day moving average price is GBX 157.17. Sareum has a one year low of GBX 92.50 ($1.12) and a one year high of GBX 455 ($5.50).

Receive SAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sareum and its competitors with MarketBeat's FREE daily newsletter.

SAR Stock News Headlines

Sareum Holdings PLC : Subscription to raise £1.63m to progress SDC-1801
Sareum Holdings PLC : Result of AGM
See More Headlines
Receive SAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sareum and its competitors with MarketBeat's FREE daily newsletter.

SAR Company Calendar

Today
8/12/2022
Next Earnings (Estimated)
10/31/2022

Industry, Sector and Symbol

Industry
Drug Manufacturers - Major
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£47,204.00
Cash Flow
GBX 8.42 per share
Book Value
GBX 8.40 per share

Miscellaneous

Free Float
N/A
Market Cap
£117.42 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Tim J. Mitchell Ph.D. (Age 62)
    Founder, CEO & Exec. Director
    Comp: $189.41k
  • Dr. John C. Reader Ph.D. (Age 55)
    Founder, Chief Scientific Officer & Exec. Director
    Comp: $187.01k
  • Mr. Anthony Bunn F.C.M.A.
    FCMA, Sec.













SAR Stock - Frequently Asked Questions

How have SAR shares performed in 2022?

Sareum's stock was trading at GBX 4.90 at the beginning of the year. Since then, SAR shares have increased by 3,420.4% and is now trading at GBX 172.50.
View the best growth stocks for 2022 here
.

When is Sareum's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, October 31st 2022.
View our SAR earnings forecast
.

What other stocks do shareholders of Sareum own?

What is Sareum's stock symbol?

Sareum trades on the London Stock Exchange (LON) under the ticker symbol "SAR."

How do I buy shares of Sareum?

Shares of SAR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Sareum's stock price today?

One share of SAR stock can currently be purchased for approximately GBX 172.50.

How much money does Sareum make?

Sareum (LON:SAR) has a market capitalization of £117.42 million and generates £47,204.00 in revenue each year.

How can I contact Sareum?

Sareum's mailing address is Unit 2A Langford Arch, London Road, Pampisford, CAMBRIDGE, CB22 3FX, United Kingdom. The official website for the company is www.sareum.co.uk. The company can be reached via phone at +44-1223-497700.

This page (LON:SAR) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.